Beijing Kangzhen Biotechnology

Beijing Kangzhen Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of innovative cell therapies for cancer. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) technology, aiming to address unmet medical needs in hematological malignancies and solid tumors. Its lead pipeline candidates include KZ-001, a CD19-targeted CAR-T therapy, and KZ-002, which targets BCMA for the treatment of multiple myeloma. Kangzhen Biotechnology utilizes proprietary engineering platforms to enhance the safety, efficacy, and persistence of its cell products. The company operates its own GMP-compliant manufacturing facility to support clinical development and future commercialization. Through its robust R&D efforts, Kangzhen seeks to provide transformative and accessible treatment options for patients with refractory cancers.